Amount of interleukin-1β and interleukin-1 receptor antagonist in periodontitis and healthy patients

被引:32
|
作者
Gilowski, Lukasz [1 ]
Wiench, Rafal [2 ]
Plocica, Iwona [2 ]
Krzeminski, Tadeusz Faustyn [1 ]
机构
[1] Med Univ Silesia, Sch Med, Div Dent, Chair & Dept Pharmacol, PL-41808 Zabrze, Poland
[2] Med Univ Silesia, Sch Med, Div Dent, Chair & Dept Conservat Dent Endodont, PL-41808 Zabrze, Poland
关键词
Interleukin-1; beta; Interleukin-1 receptor antagonist; Chronic periodontitis; Gingival crevicular fluid; GINGIVAL CREVICULAR FLUID; BONE-RESORBING ACTIVITY; RHEUMATOID-ARTHRITIS; INFLAMMATION; METAANALYSIS; EXPRESSION; IL-1-BETA; DISEASE; STRESS;
D O I
10.1016/j.archoralbio.2014.04.007
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective: Regulation of interleukin-1 beta (IL-1 beta) is a critical element of immune responses in health and disease. Additional research is required to determine the levels of interleukin-1 receptor antagonist (IL:1ra) sufficient to inhibit inteleukine-1-induced responses in periodontium. The aim of this study was to compare the levels of IL-1 beta, IL-1ra in gingival crevicular fluid samples obtained from periodontitis and healthy patients. Design of the study: The periodontitis group consisted of 50 patients (F-31, M-19) with chronic periodontitis. The control group consisted of 30 periodontally healthy subjects (F-19, M-11). Oral hygiene index-simplified, gingival index, pocket depth, clinical attachment level were measured. The concentrations of interleukins in gingival crevicular fluid were measured by the ELISA technique. Results: The total amounts of interleukin-1 beta and IL-1ra were significantly higher in periodontitis group than in the control group (P < 0.05). The levels of each cytokine were reported also as moles. In the control group there were 800-times more moles/sample of IL-1ra than IL-1 beta. In periodontitis group nearly 300-times more moles/sample of IL-1ra was obtained. The significant positive Spearman's rank correlations was identified between both concentrations (R = 0.39; P < 0.05) and total amounts (R = 0.31; P < 0.05) of cytokines in the periodontitis group. Conclusion: The increased secretion of IL-1ra in periodontitis is not adequate to "curb" the release of IL-1 beta. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:729 / 734
页数:6
相关论文
共 50 条
  • [21] Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease
    Cominelli, F
    Pizarro, TT
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 : 49 - 53
  • [22] Interleukin-1α, interleukin-1β and interleukin-1 receptor antagonist share a common U-shaped recognition epitope on interleukin-1 receptor surface
    Ma, Huaijun
    Liu, Jie
    Wu, Wei
    He, Ping
    JOURNAL OF MOLECULAR RECOGNITION, 2022, 35 (09)
  • [23] INTERLEUKIN-1 RECEPTOR ANTAGONIST COMPETITIVELY INHIBITS THE BINDING OF INTERLEUKIN-1 TO THE TYPE-II INTERLEUKIN-1 RECEPTOR
    GRANOWITZ, EV
    CLARK, BD
    MANCILLA, J
    DINARELLO, CA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (22) : 14147 - 14150
  • [24] INTERLEUKIN-1 RECEPTOR ANTAGONIST COMPETITIVELY INHIBITS THE BINDING OF INTERLEUKIN-1 TO THE TYPE-II INTERLEUKIN-1 RECEPTOR
    GRANOWITZ, EV
    MANCILLA, J
    CLARK, BD
    DINARELLO, CA
    CLINICAL RESEARCH, 1991, 39 (02): : A462 - A462
  • [25] Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites
    Ishihara, Y
    Nishihara, T
    Kuroyanagi, T
    Shirozu, N
    Yamagishi, E
    Ohguchi, M
    Koide, M
    Ueda, N
    Amano, K
    Noguchi, T
    JOURNAL OF PERIODONTAL RESEARCH, 1997, 32 (06) : 524 - 529
  • [26] Localisation of mRNA for interleukin-1 receptor and interleukin-1 receptor antagonist in the rat ovary
    Wang, LJ
    Brannstrom, M
    Cui, KH
    Simula, AP
    Hart, RP
    Maddocks, S
    Norman, RJ
    JOURNAL OF ENDOCRINOLOGY, 1997, 152 (01) : 11 - 17
  • [27] Interleukin-1 and the interleukin-1 receptor antagonist gene polymorphisms study in patients with rheumatoid arthritis
    Allam, I.
    Djidjik, R.
    Ouikhlef, N.
    Louahchi, S.
    Raaf, N.
    Behaz, N.
    Abdessemed, A.
    Khaldoun, N.
    Tahiat, A.
    Bayou, M.
    Ladjouze-Rezig, A.
    Ghaffor, M.
    PATHOLOGIE BIOLOGIE, 2013, 61 (06): : 264 - 268
  • [28] Interleukin-1β, Interleukin-1 Receptor Antagonist, and Soluble Interleukin-1 Receptor Type II Secretion in Chronic Fatigue Syndrome
    Joseph G. Cannon
    Jonathan B. Angel
    Leslie W. Abad
    Edouard Vannier
    Maria D. Mileno
    Laura Fagioli
    Sheldon M. Wolff
    Anthony L. Komaroff
    Journal of Clinical Immunology, 1997, 17 : 253 - 261
  • [29] ROLE OF INTERLEUKIN-1 AND THE THERAPEUTIC POTENTIAL OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN SEPSIS
    FISHER, CJ
    OPAL, SM
    LOWRY, SF
    SADOFF, JC
    LABRECQUE, JF
    DONOVAN, HC
    LOOKABAUGH, JL
    LEMKE, J
    PRIBBLE, JP
    STROMATT, SC
    VIGERS, GP
    RUSSELL, DA
    THOMPSON, RC
    CIRCULATORY SHOCK, 1994, 44 (01) : 1 - 8
  • [30] INHIBITION BY INTERLEUKIN-1 RECEPTOR ANTAGONIST OF INVIVO ACTIVITIES OF INTERLEUKIN-1 IN MICE
    MENGOZZI, M
    BERTINI, R
    SIRONI, M
    GHEZZI, P
    LYMPHOKINE AND CYTOKINE RESEARCH, 1991, 10 (05): : 405 - 407